Detecting clinically actionable variants in the 3′ exons of PMS2 via a reflex workflow based on equivalent hybrid capture of the gene and its pseudogene

[1]  Chang Liu,et al.  Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog. , 2018, The Journal of molecular diagnostics : JMD.

[2]  A. Prakash,et al.  The changing landscape of Lynch syndrome due to PMS2 mutations , 2018, Clinical genetics.

[3]  Mauricio O. Carneiro,et al.  Scaling accurate genetic variant discovery to tens of thousands of samples , 2017, bioRxiv.

[4]  Kyle A. Beauchamp,et al.  Development and validation of an expanded carrier screen that optimizes sensitivity via full-exon sequencing and panel-wide copy-number-variant identification , 2017, bioRxiv.

[5]  C. Gau,et al.  Multigene Panel Testing Provides a New Perspective on Lynch Syndrome. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Blum,et al.  The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program , 2017, Journal of Genetic Counseling.

[7]  H. P. Kang,et al.  Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment , 2016, bioRxiv.

[8]  P. Devilee,et al.  Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome , 2016, Human mutation.

[9]  H. P. Kang,et al.  Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing , 2016, PeerJ.

[10]  John Salvatier,et al.  Probabilistic programming in Python using PyMC3 , 2016, PeerJ Comput. Sci..

[11]  H. Lynch,et al.  Lynch syndrome in the 21st century: clinical perspectives. , 2016, QJM : monthly journal of the Association of Physicians.

[12]  R. Hofstra,et al.  Review: Clinical aspects of hereditary DNA Mismatch repair gene mutations. , 2016, DNA repair.

[13]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[14]  Yuya Kobayashi,et al.  Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. , 2015, JAMA oncology.

[15]  Alexa B. R. McIntyre,et al.  Extensive sequencing of seven human genomes to characterize benchmark reference materials , 2015, Scientific Data.

[16]  Yanming Feng,et al.  A Comprehensive Strategy for Accurate Mutation Detection of the Highly Homologous PMS2. , 2015, The Journal of molecular diagnostics : JMD.

[17]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[18]  J. Zook,et al.  Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls , 2013, Nature Biotechnology.

[19]  W. Rubinstein,et al.  American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[21]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[22]  J. Swensen,et al.  The frequency of previously undetectable deletions involving 3′ Exons of the PMS2 gene , 2013, Genes, chromosomes & cancer.

[23]  Gabor T. Marth,et al.  Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.

[24]  J. Swensen,et al.  Avoidance of pseudogene interference in the detection of 3′ deletions in PMS2 , 2011, Human mutation.

[25]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[26]  Pinar Bayrak-Toydemir,et al.  Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes , 2010, Human mutation.

[27]  A. Green,et al.  Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of lynch syndrome patients , 2010, Human mutation.

[28]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[29]  W. Foulkes,et al.  Inherited susceptibility to common cancers. , 2008, The New England journal of medicine.

[30]  J. Hainfellner,et al.  RNA‐based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference , 2008, Human mutation.

[31]  D. Bonthron,et al.  Extensive gene conversion at the PMS2 DNA mismatch repair locus , 2007, Human mutation.

[32]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Charis Eng,et al.  Highly penetrant hereditary cancer syndromes , 2004, Oncogene.

[34]  D. Bonthron,et al.  Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. , 2004, American journal of human genetics.

[35]  H. Lynch,et al.  Cancer Genetics in the New Era of Molecular Biology , 1997, Annals of the New York Academy of Sciences.

[36]  R. Fitzgibbons,et al.  Update on the differential diagnosis, surveillance and management of hereditary non-polyposis colorectal cancer. , 1995, European journal of cancer.

[37]  E. S. Pearson,et al.  THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .

[38]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[39]  Hongseok Yang,et al.  Probabilistic Programming , 1972 .